We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-2.48%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$812B
AUM Growth
-$55.8B
Cap. Flow
-$18.8B
Cap. Flow %
-2.31%
Top 10 Hldgs %
32.22%
Holding
3,109
New
91
Increased
2,002
Reduced
738
Closed
70

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$3.81B
2
XYZ
Block Inc
XYZ
+$1.46B
3
ACN icon
Accenture
ACN
+$1.23B
4
GILD icon
Gilead Sciences
GILD
+$1.15B
5
VLO icon
Valero Energy
VLO
+$1.05B

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$4.61B
2
META icon
Meta Platforms (Facebook)
META
+$2.06B
3
TSLA icon
Tesla
TSLA
+$1.81B
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.72B
5
AMZN icon
Amazon
AMZN
+$1.59B

Sector Composition

Rank Sector Weight
1 Technology 30.44%
2 Healthcare 13.92%
3 Financials 12.3%
4 Consumer Discretionary 10.98%
5 Communication Services 9.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LXRX icon
2926
Lexicon Pharmaceuticals
LXRX
$1.05B
$43K ﹤0.01%
92,248
+14,746
+19% +$9.3K
OPI
2927
DELISTED
Office Properties Income Trust
OPI
$43K ﹤0.01%
92,441
+41,400
+81% +$35.3K
SGMT icon
2928
Sagimet Biosciences
SGMT
$584M
$43K ﹤0.01%
+12,918
New +$54.2K
SLDB icon
2929
Solid Biosciences
SLDB
$972M
$43K ﹤0.01%
+11,558
New +$49.5K
BGFV
2930
DELISTED
Big 5 Sporting Goods
BGFV
$42K ﹤0.01%
42,900
BMEA icon
2931
Biomea Fusion
BMEA
$92.8M
$42K ﹤0.01%
19,352
SERA icon
2932
Sera Prognostics
SERA
$79.1M
$42K ﹤0.01%
11,333
TOON icon
2933
Kartoon Studios
TOON
$38.7M
$42K ﹤0.01%
66,240
PED icon
2934
PEDEVCO
PED
$150M
$41K ﹤0.01%
2,875
BEEM icon
2935
Beam Global
BEEM
$25.8M
$40K ﹤0.01%
19,600
QIPT
2936
DELISTED
Quipt Home Medical
QIPT
$40K ﹤0.01%
16,802
+1,031
+7% +$2.83K
SCPH
2937
DELISTED
scPharmaceuticals
SCPH
$40K ﹤0.01%
15,143
CHRS icon
2938
Coherus Oncology
CHRS
$181M
$39K ﹤0.01%
48,153
+7,984
+20% +$9.19K
KG
2939
Kestrel Group
KG
$66.3M
$39K ﹤0.01%
3,402
PROK icon
2940
ProKidney
PROK
$304M
$38K ﹤0.01%
43,108
+2,630
+6% +$3.65K
LXEO icon
2941
Lexeo Therapeutics
LXEO
$400M
$37K ﹤0.01%
10,425
PMVP icon
2942
PMV Pharmaceuticals
PMVP
$67.2M
$37K ﹤0.01%
33,600
ACHV icon
2943
Achieve Life Sciences
ACHV
$687M
$36K ﹤0.01%
13,474
BTMD icon
2944
Biote Corp
BTMD
$40.7M
$36K ﹤0.01%
10,709
DIBS icon
2945
1stdibs.com
DIBS
$163M
$36K ﹤0.01%
+11,728
New +$42.1K
LRMR icon
2946
Larimar Therapeutics
LRMR
$454M
$36K ﹤0.01%
16,310
+858
+6% +$2.71K
UP icon
2947
Wheels Up
UP
$190M
$36K ﹤0.01%
1,764
ATOS icon
2948
Atossa Therapeutics
ATOS
$23.5M
$35K ﹤0.01%
3,413
DXLG icon
2949
Destination XL Group
DXLG
$33M
$35K ﹤0.01%
23,334
QVCGA
2950
DELISTED
QVC Group Inc Series A
QVCGA
$35K ﹤0.01%
3,417

Similar funds

T. Rowe Price Associates's Q1 2025 Portfolio in Review

As of Q1 2025, T. Rowe Price Associates held 3,109 positions worth $812B, down 6.4% from $867B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

T. Rowe Price Associates's Q1 2025 filing shows 91 new, 2,002 increased, 738 reduced and 70 closed positions. Its largest new stake was T. Rowe Price Value ETF: 8,943,567 shares worth $283M. The largest sale was NVIDIA, an estimated $4.61B.

By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 33% a quarter earlier, followed by Healthcare and Financials.

  • T. Rowe Price Associates's largest Q1 2025 buy was T. Rowe Price Value ETF: 8,943,567 shares worth $283M.
  • T. Rowe Price Associates added most to Broadcom in Q1 2025, an estimated $3.81B increase.
  • T. Rowe Price Associates's biggest Q1 2025 reduction was NVIDIA, cutting an estimated $4.61B.
  • T. Rowe Price Associates fully exited Summit Materials, Inc. Class A Common Stock in Q1 2025, selling an estimated $271M.
  • T. Rowe Price Associates's ten largest holdings make up 32% of its $812B portfolio in Q1 2025.
  • T. Rowe Price Associates opened 91 new positions and closed 70 in Q1 2025.
  • T. Rowe Price Associates's portfolio value fell 6.4% quarter-over-quarter to $812B.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.